zeushield cytotoxic t lymphocytes

Zeushield Cytotoxic T Lymphocytes are a form of autologous CAR-T cell therapy developed by Hunan Zhaotai Yongren Medical Innovation. These engineered T cells express chimeric antigen receptors targeting CD80, CD86, and PD-L1, which are immune checkpoint molecules often upregulated in cancer cells. By inhibiting these targets, the therapy aims to enhance anti-tumor immune responses by overcoming tumor-induced immunosuppression. The primary indication is for neoplasms, with clinical development focused on relapsed or refractory non-small cell lung cancer (NSCLC) and other respiratory diseases[1][3][4].

Brand names

Zeushield

Other names

zeushield cytotoxic t lymphocytesZ CtlsZeushield Cytotoxic T Lymphocyte